Secondary Ammonia Scavenge With Glycerol Phenylbutyrate Improves Hyperammonemia Following Portosystemic Shunting.

hepatic encephalopathy minimal hepatic encephalopathy

Journal

JPGN reports
ISSN: 2691-171X
Titre abrégé: JPGN Rep
Pays: United States
ID NLM: 101773885

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 04 09 2021
accepted: 18 04 2022
medline: 12 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: epublish

Résumé

Portosystemic shunts are used to treat portal hypertension arising from extrahepatic portal venous obstruction. They decompress the portal system by allowing intestinal blood to bypass the liver and enter directly into the systemic circulation. These shunts increase the risk of minimal hepatic encephalopathy and altered neurodevelopmental outcomes in affected children. Treatment options are limited and have been extrapolated from those used in cirrhosis. We describe the use of glycerol phenylbutyrate as an alternate management strategy. A 3-year-old boy underwent distal splenorenal shunt for refractory variceal bleeding secondary to portal hypertension. He had neurologic deterioration and hyperammonemia refractory to traditional management strategies. Glycerol phenylbutyrate was initiated and resulted in a sustained improvement in ammonia levels, behavior, and school performance. This case illustrates the successful use of glycerol phenylbutyrate in a noncirrhotic patient with Portosystemic shunt and minimal hepatic encephalopathy refractory to conventional management strategies.

Identifiants

pubmed: 37168626
doi: 10.1097/PG9.0000000000000210
pmc: PMC10158269
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e210

Informations de copyright

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Clin Liver Dis. 2019 Nov;23(4):781-807
pubmed: 31563222
J Pediatr Gastroenterol Nutr. 2010 Dec;51(6):766-72
pubmed: 20890215
Hepatology. 2014 Aug;60(2):715-35
pubmed: 25042402
Gastroenterol Nurs. 2019 May/Jun;42(3):277-285
pubmed: 31145253
Hepatology. 2014 Mar;59(3):1073-83
pubmed: 23847109

Auteurs

Simone Kortbeek (S)

From the Section of Pediatric Gastroenterology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Christy Gilkes (C)

Section of Medical Genetics, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Aneal Khan (A)

Pediatrician and Medical Geneticist M.A.G.I.C. Clinic Ltd. in Calgary and Vancouver, Adjunct Professor of Pediatrics, University of Calgary, Calgary, AB, Canada, Metabolic Consultant, Department of Pediatrics, Saskatchewan Health Authority.

Alfred K Yeung (AK)

From the Section of Pediatric Gastroenterology, Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Classifications MeSH